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ABSTRACT
Background: Prostate cancer and its treatment may
impact physically, psychologically and socially;
affecting the health-related quality of life of men and
their partners/spouses. The Life After Prostate Cancer
Diagnosis (LAPCD) study is a UK-wide patient-reported
outcomes study which will generate information to
improve the health and well-being of men with prostate
cancer.
Methods and analysis: Postal surveys will be sent
to prostate cancer survivors (18–42 months
postdiagnosis) in all 4 UK countries (n=∼70 000).
Eligible men will be identified and/or verified through
cancer registration systems. Men will be surveyed
twice, 12 months apart, to explore changes in
outcomes over time. Second, separate cohorts will be
surveyed once and the design will include evaluation of
the acceptability of online survey tools. A
comprehensive patient-reported outcome measure has
been developed using generic and specific instruments
with proven psychometric properties and relevance in
national and international studies. The outcome data
will be linked with administrative health data (eg,
treatment information from hospital data). To ensure
detailed understanding of issues of importance,
qualitative interviews will be undertaken with a sample
of men who complete the survey across the UK
(n=∼150) along with a small number of partners/
spouses (n=∼30).
Ethics and dissemination: The study has received
the following approvals: Newcastle and North Tyneside
1 Research Ethics Committee (15/NE/0036), Health
Research Authority Confidentiality Advisory Group
(15/CAG/0110), NHS Scotland Public Benefit and
Privacy Panel (0516-0364), Office of Research Ethics
Northern Ireland (16/NI/0073) and NHS R&D approval
from Wales, Scotland and Northern Ireland. Using
traditional and innovative methods, the results will be
made available to men and their partners/spouses, the
funders, the NHS, social care, voluntary sector
organisations and other researchers.
BACKGROUND
Context
Prostate cancer is the most common cancer
in men (excluding non-melanoma skin
cancer) in the UK.1 Increasing incidence
and survival has resulted in a growing popu-
lation of men living with and beyond prostate
cancer: this is currently around 255 000 and
predicted to rise to 831 000 by 2040.2
Physical, psychosocial and emotional
sequelae following prostate cancer diagnosis
may result from the disease itself or treat-
ments.3 Speciﬁc physical consequences vary
with type of treatment and can affect urinary,
sexual, bowel and hormone-related function-
ing, with detrimental effects on health-
related quality of life (HRQL) for men and
their partners/spouses.4–7 Active surveillance
is increasingly recommended for the man-
agement of localised forms of prostate
cancer.8 Yet while this avoids potential side
effects of treatment, anxiety can be a
problem.9 Consequently, there is a major
challenge for health and social care services
to provide services to support men living
with and beyond prostate cancer and their
partners/spouses.
Current knowledge
The importance of capturing the patients’
perspective on how prostate cancer affects
everyday living is increasingly recognised,
with many studies now incorporating patient-
reported outcome measures (PROMs). In
one US study, HRQL was assessed for men
with localised disease, from pretreatment
until 24 months.10 At 24 months, sexual func-
tion was a problem for 43% of surgery
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patients, 37% after external beam radiotherapy and 30%
after brachytherapy. Urinary problems were reported by
7% of surgical patients, 11% after radiotherapy and 16%
after brachytherapy. An Australian population-based
study reported that men in all treatment groups had
worse sexual function than a control population at 1, 2
and 3 years. All treatment groups reported greater
urinary ‘bother’.11 In England, a survey of 1250 men
between 1 and 5 years postdiagnosis found that 38.5% of
respondents reported some degree of urinary leakage,
12.9% reported difﬁculty controlling their bowels and
58.4% reported being unable to have an erection.5
Urinary leakage was signiﬁcantly associated with lower
HRQL scores, while erectile dysfunction, though
common, did not signiﬁcantly impact on HRQL.5 In
Northern Ireland, psychological distress in men with
prostate cancer was shown to be predicted by cancer-
related symptoms, including urinary and bowel incontin-
ence, fatigue and insomnia.12
Current services do not meet all the needs of men
living with and beyond prostate cancer or their part-
ners/spouses.11 13–18 The results of one English survey
suggested that areas of greatest need were psychological
distress, sexuality-related issues and management of
enduring urinary symptoms.13 Elsewhere in the UK,
unmet needs were related to changes in sexual feelings
and relationships, concerns over signiﬁcant others and
fears of a recurrence.19 Men with prostate cancer also
report dissatisfaction with current follow-up care regimes
and information provision.16 20 21 Additionally, the
impact on the men’s partners/spouses is signiﬁcant.22–24
Policy
Improving outcomes has been at the heart of recent
health service reforms in the UK.25–27 Robust collection of
patient-reported outcomes (PROs) is essential to provide
evidence to inﬂuence such reforms. The National
Cancer Survivor Initiative identiﬁed the need for routine
measurement of experience and outcomes for cancer
survivors.28–30 The National Cancer PROMs Programme
was established in England in 2010 by the Department of
Health (DH). A successful methodology for population-
based PROMs surveys was established,5 31 which in 2013
was extended to all individuals 12–36 months postcolorec-
tal cancer diagnosis.32 33
The National Cancer PROMs Programme Pilot
showed that men with prostate cancer were willing to
participate (69% response; the highest of the four pilot
cancer sites).5 A 12-month follow-up demonstrated the
willingness of men to continue to engage with longitu-
dinal PROMs data collection: >80% participating in sub-
sequent data collection.34 In 2013, the largest cancer
PROMs exercise in Europe was undertaken with a survey
of 35 000 people 12–36 months following colorectal
cancer diagnosis in England. A 63% participation rate
was obtained.32 The Life After Prostate Cancer
Diagnosis (LAPCD) study will build on these
experiences to perform the largest prostate cancer
PROMs programme to date in the world.
Study aims
Primary aims
1. To describe the HRQL (eg, physical, psychosocial) of
men with prostate cancer using qualitative and quan-
titative methods;
2. To explore if and how their HRQL is associated with
or is predicted by disease, treatment and/or patient
characteristics with a view to inform development of
healthcare policy and service delivery in ways that
better meet the needs of such men and their
families;
3. To describe the levels of patient empowerment and
undertake preliminary exploration of the interaction
between patient empowerment and HRQL.
4. To undertake a normative study of men without pros-
tate cancer to determine community levels of symp-
toms for comparison.
Secondary aims
1. To undertake provider-level and health economic
analyses, and explore methods for producing robust,
meaningful comparisons of outcomes across the UK;
2. To explore the acceptability/options of electronic
PROMs data collection;
3. To explore and check the psychometric properties
(eg, reliability, validity) of the newer, less well-
established questionnaire measures used in the study;
4. To investigate the possibility of developing an item-
bank for HRQL assessment in men living with and
beyond prostate cancer;
5. To identify ‘gaps’ within existing surveys that are of
importance to patients and partners/spouses.
The study will achieve these aims through six interlink-
ing work-streams centred round the collection of
PROMs data and linkage with existing data sets
(ﬁgure 1). The study will collect data from across all
nations in the UK. While the survey questionnaire and
analysis will be similar, the methodology differs in parts
for each country in order to satisfy legal governance
requirements; this is made clear throughout the
protocol.
METHODS AND ANALYSIS
Work-stream 1: survey development and delivery
A: survey development
A survey instrument has been developed which covers a
range of generic and cancer-speciﬁc PROMs plus items
covering treatments received, sociodemographic
characteristics and the patient perspective on their
disease, treatment and experiences. The survey content
has been informed by a range of factors. These include
the incorporation of questionnaire measures which will
be used by international colleagues in similar surveys
undertaken in their countries,35 three systematic reviews
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of questionnaires used in prostate cancer research36–38
and the International Consortium for Health Outcomes
Measurement (ICHOM) recommendations for a
minimum outcomes data set for men with localised pros-
tate cancer.39 The experiences from other surveys under-
taken by the coapplicants, including scope and response
rates,40 the availability of routine demographic and
health data (to avoid duplicate collection of informa-
tion), questionnaire burden (length/number of items;
suggested ≈100 acceptable), item duplication/ redun-
dancy, costs and permission, and the priorities of differ-
ent coapplicants and advisory group members,
including service users were also considered. In addition
to the survey items included, a free-text box is included
at the end of each survey section for respondents to add
further detail or to capture any other important relevant
issues not covered in the section.
Survey measures
Generic HRQL The included measures are: (1) EQ-5D: a
generic measure of health for clinical and economic
appraisal;41 (2) K-6: a measure of non-speciﬁc distress to
discriminate cases of serious mental illness from
non-cases;42 (3) the Short Warwick-Edinburgh Mental
Well-being Scale (SWEBWEMS): a positive construct of
emotional well-being;43 (4) the Social Difﬁculties
Inventory (SDI): this assesses everyday problems
experienced by patients with cancer, including
difﬁculties with everyday living, money and employment
and relationships.44–46 Three individual SDI items on
difﬁculty with sexual matters (covered in detail
elsewhere), housing (poorly endorsed in the pilot work)
and any other difﬁculty (addressed in the free-text
boxes) have been excluded.
Cancer-specific HRQL. These measures include: (1) the
Expanded Prostate Cancer Index Composite short form
(EPIC-26): Urinary Incontinence, Urinary Irritative/
Obstructive, Bowel, Sexual, and Hormonal subscales;47
(2) European Organization for Research and Treatment
of Cancer Prostate Cancer module (EORTC PR25):
sexual subscale (two items);48 49 (3) medication/devices
for erectile dysfunction:50 items amended to avoid the
use of drug/trade names; (4) EORTC QLQ-C30: fatigue
subscale (three items).51
Patient clinical and sociodemographic characteristics. These
include: (1) Have you had a diagnosis of prostate cancer?
(as part of the introduction, not part of main survey); (2)
treatment items informed by prostate cancer clinicians
and experts; (3) comorbidity item (a list of possible
conditions); (4) standard sociodemographic items
informed by the Ofﬁce for National Statistics and other
sources; (5) support for previous mental health
problems, taken from National Comorbidity Survey;52 an
item about carer status included in recognition of the
growing number of carers.
Patient perspective measures. The included measures are:
(1) the Decision Regret Scale which provides an
indication of healthcare postdecision regret at a set
moment in time53 and (2) the Bulsara Patient
Empowerment Scale which taps into the construct of
how much control patients feel they have over their
experience of their illness and its diagnosis, treatment
and follow-up.54
The survey has been piloted in a prostate cancer clinic
in Leeds and in a group of service users. Cognitive
Figure 1 Study overview.
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testing has been carried out by the approved survey pro-
vider (Picker Institute Europe).
The Scottish version of the survey will also include a
question asking respondents whether or not they give
consent for their responses to be linked to other
Scottish health and care data sets. This will be added to
the end of the questionnaire, which is the standard
approach used for patient experience surveys in
Scotland.
B: survey delivery
Men who are between 18 and 42 months postdiagnosis
of prostate cancer will be eligible for inclusion in the
study. Eligible men will be identiﬁed through cancer
registration systems in England, Wales and Northern
Ireland, and through hospital activity data in Scotland
(with veriﬁcation of a cancer diagnosis by cancer regis-
tration records). Two discrete cohorts of men will be sur-
veyed in each UK nation (see table 1 and ﬁgure 2 for
more information on the cohorts, timelines and
expected numbers).
Cohort 1 (England) and cohort 2 (Wales/NI/Scotland)
Men living in England will be surveyed ﬁrst, followed
shortly by the devolved nations. The ﬁrst cohorts for
each nation will be resurveyed 12 months after the ori-
ginal survey to enable longitudinal assessment of out-
comes. After review of the results from the ﬁrst cohorts,
minor modiﬁcations will be made to the survey instru-
ment (if needed) and repeat cognitive testing will be
undertaken (if changes made).
Cohort 3 (normative sample; NI)
A group of men without prostate cancer will be surveyed
as a normative sample, using a similar version of the
questionnaire (removing any prostate cancer-speciﬁc
questions). This normative sample will be age and
deprivation level matched with the prostate cancer
group.
Cohort 4 (England) and cohort 5 (Wales/NI/Scotland)
A second new cohort will be surveyed in each nation,
identiﬁed in the same way as the ﬁrst cohort, but diag-
nosed during a later time period. The survey instrument
will be the same unless review of the ﬁrst cohort results
suggests modiﬁcations should be made. The men
included in this part of the study will be given the
opportunity to complete the survey electronically, with
online access via the study website. The sociodemo-
graphic and clinical characteristics of responders from
both modes of administration will be compared. The
response rate of the men in the second cohorts will be
compared with the response rate of those in the ﬁrst
‘paper only’ cohorts.
Exclusions
Only men managed by a multidisciplinary team (MDT)
within an NHS Hospital Trust/Health Board will be
eligible for the study. Individuals will be excluded if they
are eligible for inclusion in the National Prostate Cancer
Audit (NPCA), which is surveying men living in England
and Wales diagnosed with localised prostate cancer from
1 April 2014. Men treated at the four hospitals in
England participating in the True NTH Supported
Self-Management and Follow Up Care Programme55 will
be excluded to avoid burdening men with repeated
surveys.
Methodology
The methods for delivering the survey and the subse-
quent data ﬂows are outlined in ﬁgure 3. These vary
within each nation due to differing legal and govern-
ance processes and guidelines. The methodology for
England (the largest portion of the survey) is outlined
here. Deviations from this methodology in the other
nations are summarised below and in table 1.
England
The methodology follows that successfully used by the
National Colorectal PROMs Survey, England 2013.32
Brieﬂy, the National Cancer Registration and Analysis
Service (NCRAS), study team and funder will write to
the Chief Executive and prostate cancer MDT lead of
each Trust to seek their permission to survey men
treated by their Trust. Trusts will be offered the chance
to verify the list of identiﬁed patients and ﬁlter any
patients where contact would be inappropriate. For the
Trusts that agree to take part, the NCRAS will extract a
list of eligible men and send this securely to NHS Digital
for up-to-date address tracing and death checks
(48 hours prior to mailing). On completion of these
checks, the information will be passed on to the
appointed survey provider, Picker Institute Europe.
The survey will be sent out with a covering letter from
the treating NHS Trust’s Chief Executive and MDT lead
and a participant information sheet. All documents will
indicate that the survey is only to be completed if the
patient has received a diagnosis of prostate cancer. A
double-windowed envelope method will be used to
reduce the chances of someone other than the
addressee opening the survey. A translation sheet will be
included which, in the 20 most spoken minority
languages in the UK, informs participants that if they
have any questions, or would like to speak to an
interpreter, they can call the study helpline and they can
then complete the survey over the phone in their
preferred language.
Patients who agree to participate will complete the ques-
tionnaire which will be returned in prepaid envelopes to
Picker Institute Europe. The questionnaires will not
contain any personal information (ie, no names or
addresses) but will be assigned a unique reference
number (URN). The URN can be linked back to the ori-
ginal patient list in order to keep track of which men
have returned the survey or have opted out (by return-
ing the survey blank or phoning the dedicated survey
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Table 1 Overview of study methodology within each nation
England (cohorts 1 and 4)
Wales (cohorts
2 and 5)
Northern Ireland
(cohorts 2 and 5) Scotland (cohorts 2 and 5)
Normative study
(cohort 3)
Data source Cancer registry Cancer registry Cancer registry Hospital admissions BSO
Confirmation of
diagnosis and eligibility
Prostate MDT lead Prostate MDT lead Prostate MDT lead plus nurse
check for unstaged cases
Hospital admission for prostate cancer plus
cancer registration in relevant time period
Exclusions Men eligible for NPCA /true NTH Men eligible for NPCA List from protocol Men with previous
prostate cancer
Death checks NHS Digital NHS Digital BSO NRS/NHSCR/CHI BSO
Survey mail-out Picker Picker Cancer registry Picker Picker
Language English English/Welsh English English
Survey dates Cohort 1: November
2015–February 2016
Resurvey: November
2016–February 2017
Cohort 4: January 2017–March
2017
Cohort 2: June 2016–August 2016
Resurvey: June 2017–August 2017
Cohort 5: January 2017–March 2017
May 2016–July 2016
Estimated survey
numbers*
Cohort 1: n=60 000
Resurvey: n=42 000
Cohort 4: n=15 000
Cohort 2: n=4000
Resurvey: n=2800
Cohort 5: n=2000
Cohort 2: n=2000
Resurvey: n=1400
Cohort 5: n=1000
Cohort 2: n=3600
Resurvey: n=2500
Cohort 5: n=1800
n=4000
Data linkages Cancer registration;
hospital admissions;
radiotherapy; patient experience
survey;
end-of-life care
Cancer registration;
hospital admissions;
radiotherapy
Cancer registration;
hospital admissions;
radiotherapy
Cancer registration;
hospital admissions;
radiotherapy
(linkage will only be possible where
responding patients have given their
consent)
Telephone interviews Cohort 1: n=120
Follow-up interviews: n=60
Cohort 2: n=20 Cohort 2: n=20 Cohort 2: n=20 Not applicable to this
cohort
*Estimates represent the total number of men eligible for inclusion (before death checks); resurvey estimates are based on a 70% response to first surveys.
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helpline). Two reminders will be sent (with additional
death checks performed each time). Picker Institute
Europe will scan the completed surveys, transcribe any
written ‘free-text’ comments and clean the data, includ-
ing removing any identifying information where patients
may have named speciﬁc Trusts or clinicians. The
cleaned electronic data will be sent back to NCRAS
using a secure transfer mechanism where they will be
linked back to the necessary patient, disease and treat-
ment information. The data set of pseudonymised
survey responses, disease and treatment information will
be forwarded, alongside a study ID number, to the
research teams for analysis.
Wales
In Wales, the methodology follows that for England with
a few minor changes. Approval will be sought at the
Health Board level rather than individual Trusts.
Following approval, eligible men will be identiﬁed
through the Welsh Cancer Intelligence and Surveillance
Unit (WCISU). The letters and patient information
sheet will be provided in Welsh and English. However,
the ﬁrst survey will only be available in English, as not
all of the items and scales included have been validated
in Welsh. Those participants that wish to complete the
questionnaire in Welsh will be able to do so by
telephoning the survey helpline and articulating their
responses to a Welsh speaker. It is hoped that
subsequent surveys will also be available in Welsh once
translation and validation of the items has been
undertaken.
Northern Ireland
The methods for undertaking the survey in Northern
Ireland follow those used for the International Cancer
Benchmarking Partnership Module 4.56 Northern
Ireland Cancer Registry (NICR) staff will compile a list
of eligible men and will conﬁrm diagnosis of prostate
cancer using ‘stage of cancer’. Where stage is missing
and a prostate cancer diagnosis cannot be conﬁrmed by
the NICR, a list of unconﬁrmed patients will be sent to
research nurses for a ﬁnal check. The lists of patients
will also be available for MDT leads to view on request.
As information from the NICR cannot be passed to an
external survey provider, Picker Institute Europe will
provide pre made-up packs, containing the survey and
Figure 2 Schematic outline of
proposed patient-reported
outcome measures data
collection.
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cover letter, each with the same URN. The cover letter
will have the logo of the Trust of residence at the time
of diagnosis and the signatures of all three Northern
Ireland Urology MDT leads. The NICR staff will print
labels with the names and addresses of the eligible men
and these labels will be cross checked against the URN
before being applied to the cover letter. A death check
will be carried out by the NICR staff (via Northern
Ireland Business Services Organisation (BSO)) 24 hours
before the surveys are posted. Patients will return the
questionnaires to Picker Institute Europe in the prepaid
envelope provided. On a fortnightly basis, Picker
Institute Europe will supply the NICR staff with a list of
the URNs for the patients who have responded and will
also provide the associated reminder letters/packs. The
NICR staff will carry out further death checks and send
up to two reminders to the non-responders.
Scotland
In Scotland, patients identiﬁed from the Scottish Cancer
Registry can only be approached through their doctor.
In previous studies, this has resulted in low response
rates (∼30%) and placed a high administrative burden
on NHS National Services Scotland and GP practices. As
such, this study will follow the methodology approved
for the 2015 Scottish Cancer Patient Experience Survey.
Information Services Division (ISD: part of NHS
National Services Scotland, Public Health and
Intelligence) will identify eligible participants using hos-
pital activity data, with cross checking against the
Scottish Cancer Registry to conﬁrm a diagnosis of pros-
tate cancer in the required timeframe. This method
means that only around 65% of Scottish men diagnosed
with prostate cancer in the required timeframe will be
sampled. The sample will also include a higher rate of
men who have had surgery to treat their prostate cancer
than the full population of men with prostate cancer.
The sample will therefore be adjusted by removing a
small number of men who have had surgery, using strati-
ﬁcation to ensure that the sample otherwise retains the
same proﬁle as the full population of Scottish men with
prostate cancer. ISD will carry out initial death checks
against National Records for Scotland (NRS) deaths
data and request current name and address for sampled
patients from the Community Health Index (CHI) data-
base. ISD will coordinate further death checking with
the Scottish NHS Central Register (NHSCR) and the
CHI database, to be run overnight before the day of
Figure 3 Study data flows.
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each mail-out. ISD will pass the mailing lists and results
of death checking to Picker Institute Europe who will
post survey packs to eligible participants using URNs to
track responses. The covering letters will be signed by
the Medical Director for the NHS Board in which the
patient currently lives (which may not be where some of
their treatment was received).
Picker Institute Europe will pass the response data to
ISD for further linkage (eg, cancer type and stage, treat-
ment information). These data will only be added where
the responding patient has given their consent for
linkage. ISD will also provide basic demographic and
treatment data for the men who have not responded to
the survey (at an aggregated level), so that the full
cohort can be described and the potential for bias in
response fully assessed. The pseudonymised Scottish
data set will then be passed to the research team.
Normative study
Many of the symptoms experienced by patients with
prostate cancer are common in the general population.
Therefore, to understand and document health and
quality of life deﬁcits experienced by patients with
prostate cancer, we need to develop an understanding of
the background levels of these symptoms in the
population. To this end, a normative study will be
conducted in Northern Ireland. Using GP registration
data, BSO will generate a reference group of 10 000
men matched by 5-year age band and deprivation
quintile to patients with prostate cancer. BSO will issue
questionnaires with participants responding
anonymously directly to Picker Institute Europe. The
normative study questionnaire has been adapted from
the main prostate cancer questionnaire, with exclusion
of questions relating speciﬁcally to the prostate cancer
diagnosis. Validated instruments were not amended. The
tool was reviewed by the study advisory groups and by a
focus group of older men in NI. A pilot survey of 500
men will be used to test response rates, bias and
acceptability of the survey to the general public.
Assuming a 33% response rate, the sample size will allow
(at 80% power and 5% conﬁdence level) observation of
a 6% difference in the proportion of 190 patients with
prostate cancer aged 80+ reporting severe difﬁculty or
inability to perform usual activities compared with the
normative population. This will allow hypothesis testing
that signiﬁcant differences in health in patients with
prostate cancer exist compared with the general
population.
Free-phone helpline/symptoms process
A 24 hour free-phone service will be provided during
the times when surveys are live. Any queries relating to
prostate cancer symptoms or disease management will
be directed to the Prostate Cancer UK (PCUK)
nurse-led telephone advice service. For other queries,
for example, the patient wishes to report they do not
have cancer or the patient does not wish to be contacted
again, an escalation process has been developed (ﬁgure
4). Procedures to rapidly manage and report any
symptoms/incidents arising from the survey have been
established. It is not possible to foresee all possible
queries that will be raised by the patients, but these
processes have been developed to deal with the issues
that have arisen in previous PROMs surveys.
Work-stream 2: qualitative research
The qualitative element of the study will consist of cross-
sectional telephone interviews in all four nations
(n=180), longitudinal follow-up telephone interviews
(England only, n=60) and analysis of free-text comments
offered by respondents in each of the seven sections of
the questionnaire.
Cross-sectional telephone interviews (year 1)
Sampling, recruitment and interviews will start ∼4–
6 weeks after survey opening (ﬁgure 5). Survey partici-
pants will be asked to tick a box indicating their interest
in taking part in a telephone interview. Using a sampling
framework, Picker Institute Europe will randomly select
individuals who have agreed to be interviewed. Sample
groups comprise the four main treatment groups:
radical prostatectomy; radical radiotherapy; systemic
therapy (hormone therapy); active monitoring (active
surveillance and watchful waiting), and a group of black
and minority ethnic (BME) men from across the treat-
ments groups. Approximately 100 men will be inter-
viewed in England and 50 men from across the 3
devolved nations (NI /Wales/Scotland). There may be
subtle differences in the processes for contacting men
across the different nations.
Approximately ﬁve times, the required number of
men will be identiﬁed by Picker for each group in order
to meet the target of completed interviews. Picker will
then send the names and addresses of the selected men
to the research team. From this randomised sample, the
research team will then purposively select men for inter-
view to include a range of interviewees in terms of age,
marital status, time since diagnosis, sexual orientation
and prostate cancer-related problems.
The research team will send selected men an invita-
tion pack containing a letter, participant information
sheet, consent form and reply slip (for them to respond
with their telephone number and email address, should
they wish to take part in the interview). A reminder
letter will be sent to non-responders after 2 weeks.
Researchers will contact responders by phone/email
and arrange a date/time for the telephone interview for
approximately a week (but more than 48 hours) later. If
there is no reply at the set interview time, the researcher
will try to contact the participant by telephone/email to
arrange another time on up to two separate occasions
over the following 2 weeks, after which the researcher
will stop trying to contact the individual.
A further sample group comprising partners/spouses
of men with prostate cancer will be interviewed (n=20 in
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England and n=10 across the three devolved nations).
The survey will ask men to indicate on a tick box
whether their partner/spouse (should they have one)
would be interested in being interviewed. Partners will
be sampled by Picker according to treatment type and
sociodemographic characteristics of the respondent
(ﬁve times the required number). Contact details will be
sent by Picker to the research team. The research team
will then purposively select a small group to be invited
to be interviewed.
The research team will then write to the respondent
informing them that the researchers would like to inter-
view their partner. The respondent will be asked to give
the enclosed invitation letter, participant information
sheet, consent form and reply slip to their partner. A
reminder letter will be sent to non-responders after
2 weeks. Once a partner reply slip is received, a
researcher will contact them by phone/email and
arrange a date/time for the telephone interview to take
place (procedure as outlined above for the
participants).
The consent form will be read through with the indi-
vidual (patient or partner) over the phone immediately
prior to the interview taking place. Verbal consent to
participate in the study and for audio-recording of the
interview will be obtained. The interviewer will initial
the tick boxes on the consent forms as they read them
through, date and sign two copies and offer to send one
copy to the patient/partner. Completed consent forms
will be stored in a locked ﬁling cabinet within a locked
ofﬁce in the University of Southampton or Oxford
Brookes University.
Two separate recordings will be made, one for consent,
the other for the interview. Audio ﬁles recording consent
will be labelled and stored in the study’s secure data
repository. Researchers will ensure that interview
Figure 4 Patient query
escalation process.
Downing A, et al. BMJ Open 2016;6:e013555. doi:10.1136/bmjopen-2016-013555 9
Open Access
group.bmj.com on December 8, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
recordings are anonymised by deleting any identiﬁable
information that interviewees may have inadvertently dis-
closed. The recordings will then be transcribed verbatim
by professional transcribers who have signed conﬁdential-
ity agreements with either the University of Southampton
or Oxford Brookes University.
Data collection and analysis will be synchronous, allow-
ing the interview team to be aware of emerging themes
while data collection continues. Three trained and
experienced researchers will conduct the telephone
interviews. Regular meetings will take place throughout
the data collection process to review progress, interview
techniques and discuss preliminary ﬁndings.
Longitudinal interviews (year 2)
At the completion of the ﬁrst interview, the interviewer
will ascertain whether the participant might be willing to
take part in a second interview 12 months later. Those
who agree to a second interview will be contacted by
telephone 12 months later and willingness to be inter-
viewed again conﬁrmed. If so, a date/time will be set for
the interview following the same methodology outlined
for the year 1 interviews. Baseline interviews with each
participant will be read by researchers prior to the
second interview to ensure that issues of concern can be
revisited to ascertain whether those issues have
improved, worsened or been supplanted by other con-
cerns during the intervening period. Owing to time con-
straints, the longitudinal interviews will take place in
England only.
Topic guides
A literature review and meta-synthesis of qualitative
studies exploring the experiences of men with prostate
cancer and their partners has been undertaken.57
First-order, second-order and third-order constructs
from this analysis have informed interview topic guides
and ensure that data collected include important
Figure 5 Outline of qualitative
data collection process.
10 Downing A, et al. BMJ Open 2016;6:e013555. doi:10.1136/bmjopen-2016-013555
Open Access
group.bmj.com on December 8, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
concerns previously identiﬁed while allowing further
issues to emerge. The topic guides will be pilot tested
with user representatives.
PhD substudy
As the basis of a PhD studentship, a substudy will aim to
explore the experiences and needs of younger men with
prostate cancer and their partners, in order to identify
ways that couples can be better supported. The substudy
will seek to recruit and interview 25 younger men with
prostate cancer and their partners, and to conduct a
second interview 9–12 months later with those who
agree.
Free-text questions
At the end of each of the seven sections of the question-
naire, participants will be invited to provide free-text
comments expanding on their responses to the closed
questions. At the end of the survey, a ﬁnal free-text ques-
tion will ask participants whether there is anything else
they would like to comment on regarding their life since
diagnosis, which was not covered by the survey. The
responses to these questions will be analysed using a
variety of methods to identify insights and determine
patterns in participant experiences (see the Data analysis
and reporting section for more details).
Work-stream 3: data linkage
The study will use a number of routine data sets in
order to maximise the amount of clinical and treatment
information available (see ﬁgure 6):
Cancer registration: Questionnaire data from respon-
dents will be linked back to the cancer registration data
within the relevant nation to provide staging informa-
tion, conﬁrmation of reported treatments and validation
of age, gender and ethnicity. The cancer registration
data will cover all eligible men in order to identify
responder bias (comparison of the respondents and
non-respondents in terms of age, deprivation etc).
Hospital admissions: These data provide information
on inpatient admissions, including treatments, hospital
of treatment, length of stay and comorbidities.
Outpatient admission data may be available for some of
the nations, and generally allows analysis of hospital
visited and specialty seen. The speciﬁc data sets are
listed in ﬁgure 6.
Radiotherapy: These data can provide information on
type of radiotherapy (long or short course), number of
fractions, intent etc. These data may not be available for
all nations (see ﬁgure 6).
Patient experience survey: In England, the annual
National Cancer Patient Experience Survey (NCPES)
investigates patients’ experiences of treatment and after-
care.58 Trust-level linkage with NCPES will allow
Figure 6 Data linkages.
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exploration of the relationships between patient experi-
ence and quality-of-life outcomes at the service provider
level. Patient experience surveys are underway in the
devolved nations but will not cover the necessary time-
frame (ie, men diagnosed between 1 April 2012 and 31
March 2014).
End-of-life care: In England, linkage with the data held
by the National End of Life Care Intelligence Network
(part of Public Health England) will be explored. These
data would provide information, for example, healthcare
usage and place of death for those men who die after
completing the survey and allow exploration of patterns
of care at the end of life.59
All linkage will be undertaken by trained staff with
approvals to work with identiﬁable data. Linkage will be
performed using combinations of identiﬁers, for
example, date of birth, sex, postcode. Once linked, the
data will be pseudonymised (names, addresses, dates of
birth, NHS numbers removed) and securely transferred
to the study team for analysis. In Scotland, linkage of
survey responses to other health and care data sets will
only be possible where responding patients have given
their consent.
Work-stream 4: benchmarking and organisational
performance
Comparison across countries (benchmarking)
The HRQL and other health-related outcomes of the
respondents will be compared, within the UK and inter-
nationally, where possible (eg, comparing with Ireland
and Australia where similar PROMs work is being under-
taken). In this study, information on generic health out-
comes will be collected through EQ-5D and
cancer-speciﬁc outcomes through EPIC-26. A common
methodology of data collection would allow meaningful
comparisons to be made. Such analyses will require
robust adjustment for casemix (age, deprivation level of
the population) and other confounding factors to
ensure that fair comparisons are made. This will depend
on the amount and quality of information across the dif-
ferent countries.
Comparison across providers (organisational performance)
Performing robust comparison across provider organisa-
tions, such as hospitals, throws up a number of meth-
odological issues,60 including correct allocation of
patients to the institution that provided their main treat-
ment, ensuring a sufﬁcient number of respondents per
hospital to allow meaningful comparison, differing
response rates by hospital and robust adjustment for
casemix. The feasibility of comparison across organisa-
tions, taking into account these issues, will be explored.
Members of the study team are experienced in analysing
the results of large-scale surveys and in the robust assess-
ment of cancer outcomes.32 61–63
Feedback of information to providers
Initial results will be reported at national and provider/
organisational level after each data collection (within
6 months of completion of data collection). This will be
performed using an electronic toolkit, already devel-
oped by the team for the colorectal PROMs work, pro-
viding a national overview and organisational-level data
compared with national averages. This will allow provi-
ders to see the responses from their patients and to
quickly identify any areas of concern. These results will
not, however, be adjusted for differences in casemix.
More detailed results taking into account the issues
described above will be disseminated to providers
through speciﬁc topic-focused reports, as well as presen-
tations and academic papers.
Work-stream 5: health economic analysis
Given the signiﬁcant volume of PROMs data collected in
this study, it is logical to explore their potential value in
contributing to more focused health economic evalu-
ation. The exploratory analyses undertaken as part of
this work-stream will be split into three areas: (1) recali-
bration of EQ-5D health outcomes using patients’ own
self-assessed values (VAS 0–100 ratings) in order to make
more meaningful comparisons with other relevant refer-
ence groups, including other cancer groups and the
general population; (2) analysis of the relationship
between EQ-5D (generic HRQL/health status) and
other (condition-speciﬁc) measures to identify any
descriptive ‘gaps’ within EQ-5D, establish the extent of
any mis-measurement and examine the potential for
remedial action; (3) examine the potential use of
EQ-5D as an indicator of performance in treatment of
patients with prostate cancer (this links in with work-
stream 4).
Work-stream 6: patient and public involvement
It is important that service users (ie, patients, along with
their partners, family and carers) are involved, through
active partnership with the project team, in contributing
as lay advisors to all aspects of this research project. This
study has incorporated a high level of patient and public
involvement (PPI) from the outset with the establish-
ment of a User advisory group (UAG) and reference
group.
User advisory group
The UAG comprises six service user members plus a
limited number of (1) health professionals and (2)
researchers, with commitment to, as well as detailed
expertise and research knowledge and experience of,
user concerns and priorities. This Group has adopted
Terms of Reference and a modus operandi based on the
NIHR ‘PPI Research Cycle Model’.64 The UAG will meet
every 3 months and the Chair is a full member of the
study team and named Coinvestigator.
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Reference group
The UAG’s work will be supported by a reference group
consisting of prostate cancer service users, partners and
family members who will be invited, as appropriate, to
provide information and views on particular issues.
Members of PCUK’s ‘On-Line Community’ (an open
forum of PCUK volunteers and bloggers) will be kept up
to date about the study and will be appraised of oppor-
tunities to contribute to advising the project on speciﬁc
matters, as and when topics requiring additional input
are identiﬁed. Those service users who express an inter-
est in offering views on the identiﬁed topic will then act,
de facto, as a member of the reference group.
Data analysis and reporting
Quantitative data analysis
Descriptive statistics will be used to report the survey
results and ‘describe’ the health outcomes of men with
prostate cancer. The outcome variables, that is, EQ-5D,
EPIC-26 and SDI, will be analysed according to stage/
severity of disease (TNM and Gleason Score, where avail-
able), treatment type, comorbidity, age, ethnic and
sociodemographic group (and other relevant variables).
These descriptive analyses will identify potential relation-
ships of interest which can be investigated further.
Regression modelling will be used to investigate associa-
tions and to identify statistically and clinically signiﬁcant
risk factors and predictors of health outcomes. In order
to be robust, analyses will require appropriate adjust-
ment for casemix and other confounding factors and
may require more complex techniques, such as the mod-
elling of hierarchies within the data (multilevel model-
ling) and post hoc weighting to overcome response bias.
Multiple imputation methods may be used to deal with
missing data. A similar methodology would be used for
international comparison of health outcomes, depend-
ing on the comparability of the survey instruments used.
Respondents from the ﬁrst cohorts (Cohorts 1 and 2)
will be resurveyed 12 months after the initial survey,
which will allow measurement of any changes in their
outcomes over time. For example, differences in EQ-5D
scores could be calculated between the two time points
and this would allow assessment of whether outcomes
improve, decline or remain static. Interpretation is difﬁ-
cult, however, as there is no information regarding the
individuals’ health before their cancer diagnosis.
Normative data from the general population will be
used, where these are available, in order to compare the
health of men with prostate cancer with those in the
general population and to assess whether their health
returns to a ‘normal’ level over time.
New instrument development is not being undertaken
as part of this work. However, there is the opportunity to
explore and check the psychometric properties of the
newer, less well-established questionnaires and to deter-
mine the most ﬁtting instruments for future prostate
cancer PROMs work using the Rasch analysis.65
Qualitative data analysis
Telephone interviews (cross-sectional and longitudinal)
Interviews will be transcribed verbatim and managed
within NVivo software (QSR International. NVivo qualita-
tive data analysis Software: version 11, 2016). A frame-
work analysis approach will be adopted: a matrix-based
approach for collating, reviewing and understanding
data.66 The researchers will read interview transcripts
from each of the groups to ensure a deep familiarisation
with the data. An initial coding framework will be devel-
oped, drawn from the interview schedule but informed
by emerging themes incorporating the experiences of
the four treatment sample groups and the BME sample.
Another coding framework will be developed for the
partner’s sample. Analysis and data collection will occur
simultaneously and new data will be compared with that
already coded to identify further themes. Speciﬁc
themes within the data will be mapped and patterns,
relationships and associations will be identiﬁed.
Inter-rater comparability testing will take place at several
points throughout the process.
Free-text comments
Free-text data, provided by survey respondents, will be
analysed using NVivo (QSR International. NVivo qualita-
tive data analysis Software: version 11, 2016) and ‘R’ soft-
ware (R Core Team). All comments will be indexed and
entered into NVivo (QSR International Pty. NVivo quali-
tative data analysis Software: version 11, 2016). Analysis
will follow three phases in a way similar to a previous
study conducted by members of the research team.67
First, random samples of comments will be read and
coded to develop a thematic framework that compre-
hensively categorises issues and identiﬁes ‘hot topics’.
Second, machine learning algorithms will be trained
and tested to retrieve comments within the larger data
set pertaining to the categories of interest. Third, a
deeper level of qualitative analysis will be conducted
relating to issues of particular interest to identify insights
and determine patterns in participant experiences.
Management and oversight
A Clinical/Scientiﬁc Advisory Group (CSAG) will be
used to provide expert knowledge for study design, inter-
pretation, analysis and reporting. The project team will
work closely with the Clinical/Scientiﬁc and User advis-
ory groups as well as clinical and methodological
opinion leaders who have agreed to collaborate. In add-
ition, a steering group has been established by PCUK
with responsibility for oversight of active performance
delivery.
The Principal Investigators, Project Managers and
other relevant team members (depending on the phase
of the study) will have weekly telephone meetings, while
the full study team will meet monthly to review progress.
The CSAG and steering group will meet every 3 months.
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DISCUSSION
It is intended that the study will provide detailed data on
which to drive forward service improvements, produce
information to help patients and their clinical teams
choose the most appropriate treatment option, optimise
the provision of post-treatment support and inform
future research. The success of this study relies on cor-
rectly identifying and contacting the eligible men
without causing undue distress, and obtaining a high
response rate from a representative sample of prostate
cancer survivors. The study results must be disseminated
widely and effectively in order to have the maximum
impact.
Ethics approval
The study has received the following approvals:
Newcastle and North Tyneside 1 Research Ethics
Committee (15/NE/0036), Health Research Authority
Conﬁdentiality Advisory Group (15/CAG/0110), NHS
Scotland Public Beneﬁt and Privacy Panel (0516-0364),
Ofﬁce of Research Ethics Northern Ireland (16/NI/
0073) and NHS R&D approval from Wales, Scotland and
Northern Ireland.
Ethical and safety considerations
The methodology will follow that adopted in previous
surveys,5 32 where the number of adverse events/symp-
toms was very low. In addition, in England, Wales and
Northern Ireland, approval will be sought from the treat-
ing Trust/MDT and they will be offered the chance to
check the list of eligible men. The ﬁrst question on the
survey will ask men whether they have ever been diag-
nosed with prostate cancer. If not, they can tick no and
return the survey and will not be contacted again. Death
checks will be carried out immediately prior to survey
mail-out; however, it must be acknowledged that even
with the most stringent checks, a small number of indivi-
duals may have died very close to the time of survey
mailing and these will receive a survey. A double enve-
lope method will be used for the mailings to mitigate
against someone other than the intended recipient
opening the survey. Despite all of these measures, it is
not possible to predict the reaction of the men who
receive a survey, for example, whether they will become
angry or upset at being contacted. The information
accompanying the survey has been carefully worded and
checked with service users and the ethics committee in
order to optimise positive reactions. In order to deal
with any adverse events/symptoms, a procedure for
rapid and timely response to, and support of, affected
individuals has been developed.
Maximising response rates
A number of methods will be employed to achieve as
high a participation rate as possible, including a media
campaign to coincide with survey mail out, the use of
social media and the PCUK online forum to promote
the survey, sending two reminder letters, which has been
shown to increase response rates, and the option to
complete the survey in a range of the most spoken
minority languages in the UK. It is known from previous
PROMs surveys that there tend to be differences in the
characteristics of those who do and do not respond, with
the elderly, ethnic minorities and those from more
socioeconomically deprived areas being less likely to par-
ticipate.5 32 If, after using the methods above, there are
differences between the responders and non-responders,
statistical techniques can be used to adjust for variation
in participation rates.
The use of electronic data collection will be explored
during the second surveys in each nation. Response
rates will be carefully examined to look at variation by
age, and other sociodemographic factors, and to see
whether response rates can be increased using elec-
tronic methods.
Dissemination plan
The study ﬁndings will be disseminated through a series
of reports, academic papers (open-access) and confer-
ence presentations, and all ﬁndings will be available on
the dedicated study website as well as the PCUK website
and online forum. These outputs will provide qualitative
and quantitative empirical knowledge of key clinical,
sociodemographic, psychosocial and service/organisa-
tional factors that predict patients with prostate cancer
generic and cancer-speciﬁc HRQL. A public access
online toolkit will provide detailed anonymised informa-
tion. The toolkit will enable each provider (NHS Trust/
Health Board, Commissioning Group, Clinical Network
or equivalent) to visualise the results for their organisa-
tion and to compare them against the national
‘average’. The study will produce a validated survey tool
for the collection of health outcomes of prostate cancer
survivors. This would be made available for use by other
organisations and researchers (dependent on appropri-
ate conditions of use).
Participant anonymity
Publications/reports on the ﬁndings of the study will
make no reference to the identities of the patients who
participated. When describing the clinical and sociode-
mographic characteristics of the sample, care will be
taken to ensure that, if any values are small numbers,
for instance, this information does not allow individuals
to be identiﬁed. Similarly, if any direct quotations are
used for illustrative purposes, they will be anonymised
and care taken to ensure that they are not inadvertently
identiﬁable.
Data storage and security
A 15-year data retention policy will be adopted for the
hard-copy data (questionnaire responses) and electronic
records held by Picker Institute Europe, with a review at
the halfway point as to whether or not ongoing retention
is justiﬁed. The records will be identiﬁed by an ID
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number with only the cancer registries (and ISD in
Scotland) able to identify participants.
For the period of the study, the pseudonymised survey
data and interview recordings and transcripts will be
stored in a secure environment provided by the Leeds
Institute of Data Analytics at the University of Leeds.
The data will be accessed by approved members of the
research team who will adhere to the agreed data secur-
ity protocol and follow the relevant codes of practice
concerning conﬁdentiality, information security and
records management.
The electronic survey data will be stored long term by
the appropriate cancer registry (in England, Wales or
NI) or by ISD in Scotland and held according to their
respective information governance arrangements.
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